Vena Cava Filter for All Patients After Severe Trauma

Until today, there was no evidence warranting the early implantation of a vena cava filter for the reduction of the risk of pulmonary embolism in patients with severe trauma and contraindication to prophylactic anticoagulation.

This article, soon to be published in the New England Medical Journal (NEJM), brings us such evidence and we surrender to it. Early prophylactic placement of a vena cava filter after severe trauma did not reduce the incidence of symptomatic pulmonary embolism or death at 90 days compared with no implantation of a filter.

This multicenter controlled trial enrolled 240 patients with severe trauma (Injury Severity Score >15; scores range from 0 to 75, and the highest the score, the highest the severity]) who had a contraindication to anticoagulation, and randomized them to filter implantation within the first 72 hours after admission vs. no implantation.


Read also: New Promising Alternatives for Mitral Regurgitation.


The primary endpoint was a composite of symptomatic pulmonary embolism at 8 to 90 days in the subgroup of patients who survived at least 7 days and who did not receive prophylactic anticoagulation during that time.

The mean age was 39 years old and the mean Injury Severity Score was 27.

Early filter implantation did not result in lower incidence of the primary endpoint (13.9% in the vena cava filter group vs. 14.4% in the control group; p = 0.98).

No patient in the filter group developed pulmonary embolism while 5 patients (14.7%) in the control group, including one who died, did experience such complication. Entrapped thrombus was found in the filter in 6 patients.

Conclusion

Early prophylactic placement of a vena cava filter in patients with severe trauma did not result in a lower incidence of symptomatic pulmonary embolism or death at 90 days vs. no filter implantation in patients with contraindication to prophylactic anticoagulation.

Original Title: A Multicenter Trial of Vena Cava Filters in Severely Injured Patients.

Reference: Kwok M. Ho et al. N Engl J Med. 2019 Jul 7. [Epub ahead of print].


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC 2026 | HI-PEITHO: Catheter-directed strategy (EKOS) in intermediate-risk acute pulmonary embolism

The treatment of intermediate-risk pulmonary embolism (PE) continues to be an area of therapeutic uncertainty. The initial PEITHO study (2014) demonstrated a reduction in...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...

AHA/ACC Guideline on the Management of Acute Pulmonary Embolism 2026

The 2026 ACC/AHA guideline for the management of acute pulmonary embolism (PE) introduces a conceptual shift by replacing the traditional “risk-based” classification with an...

FFR Assessment for the Selection of Hypertensive Patients Who Benefit from Renal Stenting

Atherosclerotic renal artery stenosis (ARAS) represents one of the main causes of secondary hypertension (HTN) and is associated with a higher risk of renal...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...

ACC 2026 | CHAMPION-AF: Left atrial appendage closure versus anticoagulation in atrial fibrillation

Can left atrial appendage closure challenge anticoagulation as the standard of care in atrial fibrillation? Atrial fibrillation (AF) is the most common sustained arrhythmia and...

ACC 2026 | CHIP-BCIS3: Impella use as support in high-risk complex PCI

The use of percutaneous ventricular support during high-risk complex PCI has been proposed as a strategy to prevent hemodynamic deterioration in patients with severe...